It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Long-term potentiation (LTP) at hippocampal CA1 synapses can be expressed by an increase either in the number (N) of AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid) receptors or in their single channel conductance (γ). Here, we have established how these distinct synaptic processes contribute to the expression of LTP in hippocampal slices obtained from young adult rodents. LTP induced by compressed theta burst stimulation (TBS), with a 10 s inter-episode interval, involves purely an increase in N (LTPN). In contrast, either a spaced TBS, with a 10 min inter-episode interval, or a single TBS, delivered when PKA is activated, results in LTP that is associated with a transient increase in γ (LTPγ), caused by the insertion of calcium-permeable (CP)-AMPA receptors. Activation of CaMKII is necessary and sufficient for LTPN whilst PKA is additionally required for LTPγ. Thus, two mechanistically distinct forms of LTP co-exist at these synapses.
Long-term potentiation at hippocampal CA1 synapses can be due to increasing the number and/or single-channel conductance of AMPA receptors. The authors show that PKA and CaMKII are necessary and together sufficient to increase single channel conductance, via insertion of calcium-permeable AMPA receptors.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 University of Bristol, Glutamate Receptor Group, School of Physiology, Pharmacology and Neuroscience, Bristol, United Kingdom (GRID:grid.5337.2) (ISNI:0000 0004 1936 7603); Seoul National University, Department of Biological Sciences, College of Natural Sciences, Seoul, Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905); Mount Sinai Hospital, Lunenfeld-Tanenbaum Research Institute, Toronto, Canada (GRID:grid.416166.2) (ISNI:0000 0004 0473 9881); University of Toronto, Department of Physiology, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
2 Mount Sinai Hospital, Lunenfeld-Tanenbaum Research Institute, Toronto, Canada (GRID:grid.416166.2) (ISNI:0000 0004 0473 9881)
3 University of Bristol, Glutamate Receptor Group, School of Physiology, Pharmacology and Neuroscience, Bristol, United Kingdom (GRID:grid.5337.2) (ISNI:0000 0004 1936 7603); Seoul National University, Department of Biological Sciences, College of Natural Sciences, Seoul, Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905); Mount Sinai Hospital, Lunenfeld-Tanenbaum Research Institute, Toronto, Canada (GRID:grid.416166.2) (ISNI:0000 0004 0473 9881)
4 Seoul National University, Department of Biological Sciences, College of Natural Sciences, Seoul, Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905)
5 Seoul National University, Department of Biological Sciences, College of Natural Sciences, Seoul, Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905); The Hospital for Sick Children, Neurosciences and Mental Health, Peter Gilgan Centre for Research and Learning, Toronto, Canada (GRID:grid.42327.30) (ISNI:0000 0004 0473 9646)
6 University of Bristol, Glutamate Receptor Group, School of Physiology, Pharmacology and Neuroscience, Bristol, United Kingdom (GRID:grid.5337.2) (ISNI:0000 0004 1936 7603)
7 Seoul National University, Department of Biological Sciences, College of Natural Sciences, Seoul, Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905); University of Toronto, Department of Physiology, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)
8 University of Bristol, Glutamate Receptor Group, School of Physiology, Pharmacology and Neuroscience, Bristol, United Kingdom (GRID:grid.5337.2) (ISNI:0000 0004 1936 7603); Seoul National University, Department of Biological Sciences, College of Natural Sciences, Seoul, Korea (GRID:grid.31501.36) (ISNI:0000 0004 0470 5905); Mount Sinai Hospital, Lunenfeld-Tanenbaum Research Institute, Toronto, Canada (GRID:grid.416166.2) (ISNI:0000 0004 0473 9881); University of Toronto, Department of Physiology, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938); University of Toronto, TANZ Centre for Research in Neurodegenerative Diseases, Toronto, Canada (GRID:grid.17063.33) (ISNI:0000 0001 2157 2938)